Advertisement

Astra-Sanofi's RSV therapy 'highly effective' against infant hospitalizations, CDC study shows

(Corrects typo in CDC agency's name in paragraph 1)

(Reuters) - AstraZeneca and Sanofi's antibody therapy was 90% effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV), a study by the U.S. Centers for Disease Control and Prevention showed on Thursday.

(This story has been refiled to correct a typo in the agency's name in paragraph 1)

(Reporting by Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta)